Reckitt Benckiser Group plc (LON:RB) Given Average Rating of “Buy” by Brokerages

Reckitt Benckiser Group plc (LON:RB – Get Rating) has been given a consensus recommendation of “N/A” by the eleven ratings firms that are currently covering the company, Marketbeat Ratings reports. The average 12 month price objective among analysts that have issued a report on the stock in the last year is GBX 7,127.27 ($87.87).

A number of research firms have recently commented on RB. Royal Bank of Canada set a GBX 5,900 ($72.74) price objective on shares of Reckitt Benckiser Group in a research note on Wednesday. Barclays set a GBX 9,300 ($114.66) price objective on shares of Reckitt Benckiser Group in a research note on Tuesday, May 3rd. UBS Group set a GBX 8,000 ($98.63) price objective on shares of Reckitt Benckiser Group in a research note on Tuesday, May 3rd. JPMorgan Chase & Co. set a GBX 8,500 ($104.80) price objective on shares of Reckitt Benckiser Group in a research note on Wednesday, April 27th. Finally, Berenberg Bank set a GBX 7,700 ($94.93) price objective on shares of Reckitt Benckiser Group in a research note on Tuesday, May 3rd.

The firm has a market cap of £48.36 billion and a price-to-earnings ratio of 40.79. The company has a debt-to-equity ratio of 116.01, a current ratio of 0.77 and a quick ratio of 0.53. Reckitt Benckiser Group has a one year low of GBX 5,782 ($71.29) and a one year high of GBX 8,020 ($98.88).

Reckitt Benckiser Group Company Profile (Get Rating)

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.

See Also